Seasons can influence the results of the methacholine challenge test

Bruno Sposato, Marco Scalese1, Andrea Pammolli2, Raffaele Scala3, Mario Naldi4

Unit of Pneumology, "Misericordia" Hospital, Grosseto, 1Institute of Clinical Physiology, National Research Council, Pisa, 2Department of Physiopathology, Experimental Medicine and Public Health, University of Siena, 3Unit of Pneumology and UTSIR, "Campo di Marte" Hospital, Lucca, 4"S. Donato" Hospital, Arezzo, Italy

Address for correspondence: Dr. Bruno Sposato, U.O. Pneumologia, Azienda Ospedaliera "Misericordia", Via Senese 161; 58100 GROSSETO, Italy. E-mail: bsposal@tin.it
Submission: 23-08-11
Accepted: 29-11-11

Original Article

Abstract:

OBJECTIVE: This study tried to evaluate whether a methacholine test may be influenced by the seasons.

METHODS: We considered 4826 consecutive subjects with normal spirometry (50.53% males; age: 35.1±16.2; forced expiratory volume in one second: 99.5±13.0%) who underwent a methacholine test for suspected asthma symptoms between 2000 and 2010. They were subdivided into four groups, like the seasons, according to the test dates.

RESULTS: A total of 1981 (41%) resulted normal (no PD20 was obtained with 2400 µg of methacholine); the others showed a mean LogPD20 of 2.52±0.5 µg. The number of subjects with bronchial hyper-responsiveness (BHR) found in autumn (789, 62.3%) was higher than in summer (583, 56.7%; P=0.03). A higher number of females and overweight/obese subjects showed a BHR in autumn compared with the other seasons. The spring mean LogPD20 value (2.48±0.48 µg) was lower if compared with the one measured in summer (2.59±0.49 µg; P<0.05). LogPD20 value was lower in females and non-smokers in spring compared with summer (P<0.05). Overweight/obese non-smokers showed a lower LogPD20 in spring and autumn compared with that in summer (P<0.05).

CONCLUSION: There was a higher probability of finding BHR in outpatients with suspected asthma in autumn and spring compared with summer. Spring is the season where BHR may be more severe. Females and overweight/obese subjects were those mainly involved in this seasonal variability of BHR.

Key words:

Airway, asthma, bronchial hyper-responsiveness, methacholine challenge test, season

Bronchial asthma is a chronic inflammatory disease characterized by a variability of bronchial obstruction. In order to confirm asthma diagnosis, it is sometimes necessary to perform a methacholine challenge test in subjects with suspected asthma symptoms but with a normal baseline spirometry and without a significant response after administering bronchodilators.[1]

There is some evidence that asthma—and especially bronchial hyper-responsiveness (BHR)—may be influenced by the seasons. In fact, patients with allergic rhinitis or asthma have allergen-related seasonal changes in BHR.[2,3]

During pollen exposure, a decrease in provocative concentration of methacholine causing a 20% fall in lung function (PC20) was found compared with what had been detected during the previous season in hyper-responsive patients with rhinitis and/or asthma.[4] Mite-allergic asthmatic patients showed an increased non-specific BHR in autumn, a possible consequence of a higher indoor mite concentration.[5,6] Especially in cold seasons, respiratory infections might also increase BHR in asthmatics.[7-11] Furthermore, climatic variations of air temperature and above all of humidity might influence the BHR and exercise-induced bronchospasm.[12,13]

Therefore, seasons seem to influence the results in the methacholine challenge test. Fruchter and Yigla[14] had already shown that the percentage of positive methacholine challenge tests was higher in winter and spring in a selected cohort of young adult patients. However, this seasonal variability may be different in the various latitudes (different vegetation and climates). We already know that age, sex, and smoking habits can influence hyper-responsiveness,[15-18] but we do not know if a methacholine test will give different results for males and females, young and elderly subjects, smokers and non-smokers, if performed in the different seasons.

The aim of this study was to evaluate if there was a seasonal variability in the prevalence of BHR and its severity measured with the methacholine test in a large number of subjects with suspected asthma living in Tuscany Italy, an area with a temperate climate.

Methods

Subjects

For the purpose of this study, we extracted from the spirometer data files of our pneumology departments of Grosseto and Arezzo (Tuscany)
5023 consecutive methacholine challenge tests performed between 2000 and 2010 and retrospectively analyzed. All these tests had been carried out to confirm or exclude an asthma diagnosis. In fact, all patients had suspected asthma symptoms (unexplained episodes of cough and/or wheezing and/or dyspnea) with a normal spirometry and therefore they were subjected to a methacholine challenge test. Four thousand eight hundred twenty-six subjects (2439 M; mean age 35.1±16.2; mean±SD of forced expiratory volume in one second [FEV$_1$]: 101.1±12.9%; mean±SD of forced vital capacity [FVC]: 99.5±13%; mean±SD of FEV$_1$/FVC: 86±7.1) were suitable for the study because they completed the test. One hundred ninety-seven subjects were excluded as they had not finished the test: Some were intolerant to testing, others interrupted the challenge because they had showed a fall in FEV$_1$>10% with the buffer solution. In those few who had repeated the methacholine test several times, only the first challenge was taken into consideration.

For every test, FEV$_1$, FEV$_1$/FVC, FVC, cumulative provocative dose of methacholine causing a 20% fall in FEV$_1$ (PD$_{20}$), smoking habits, body mass index (BMI), and the date of when the test had been carried out were taken into account.

The BMI value of 25 was used as a cut-off to subdivide normal weight or underweight (BMI<25) subjects from those overweight or obese (BMI≥25). International cut-off points for BMI, to assess overweight and obese children, were used to subdivide those aged <18 years into underweight-normal or overweight-obese subjects.[19]

All methacholine tests had been performed randomly during any of the four seasons in the period of time taken into consideration for our study. The test was carried out after a waiting list period of 2 to 3 months. Sometimes, subjects underwent the test even some years after the onset of symptoms. The methacholine test was postponed for at least 4 weeks when subjects had shown an exacerbation of symptoms or an airway infection. B$_2$-agonist bronchodilators and inhaled or systemic corticosteroids were not taken 24 hours and 3 weeks before the test had been carried out were taken into account.

The methacholine challenge tests were divided into the four seasons was fundamentally based on the different temperatures during the year in the Mediterranean area where Italy is located. In our area (Grosseto and Arezzo) the mean temperature measured in winter, spring, summer, and autumn between the year 2000 and 2010 were 7.2°C, 17.8°C, 22°C, and 17.7°C, respectively (data from the Italian Air Force Meteorological Service).

**Methacholine challenge test**

The challenge test was performed using a dosimeter method.[20] The same kind of instrument and method were used in Grosseto and Arezzo between the year 2000 and 2010. Methacholine sulfate was provided by Lofarma (Milan, Italy) and administered in aerosol form by a MEFAR MB3 dosimeter (output: 9 µl/puff; MEFAR Elettromedicali Brescia, Italy) using a model MB2 ampoule. Buffer and methacholine were diluted with distilled water and then two different progressive methacholine solutions were prepared for the test: An ampoule with a methacholine concentration of 4 mg/ml (40-µg inhalation dose) and another with a concentration of 40 mg/ml (400 µg inhalation dose). The buffer solution was administered first followed by 40 µg of methacholine, increasing the doses step by step until PD$_{20}$, was obtained or until the maximum dose of muscarinic agonist was reached. FEV$_1$ was measured after administering 40, 80, 120, 240, 400, 800, 1 600, 2 400, or 3200 µg of cumulative methacholine doses. The doses were taken from the first ampoule up to 400 µg and from the second up to 2400 or 3200 µg. At the end of exhalation during tidal breathing, the patients inhaled methacholine slowly and deeply from the nebulizer in a time of 5 seconds and then held their breaths for another 5 seconds. The test was interrupted if a fall in FEV$_1$>10% was obtained with the buffer solution. The time interval between the two steps was 2 minutes, calculated from the start of one step to the next. FEV$_1$ was measured at 30 and 90 seconds after the nebulization. An acceptable-quality FEV$_1$ at each time point was obtained. No more than two maneuvers after each dose was performed and the highest FEV$_1$ value was taken into consideration. During the first years (until the end of 2008), the maximum cumulative dose of methacholine used in the challenge was 3200 µg, whereas in the last two years (2009-2010), it was reduced to 2400 µg. As not all subjects had used the same methacholine dose cut-off and according to guidelines,[1] a high dose of methacholine is not necessary to diagnose BHR (for the high probability of a false positivity), we arbitrarily selected a cumulative 2400 µg dose as the cut-off value for all to identify hyper-responsive patients. Therefore, BHR was defined by a 20% fall in FEV$_1$, following a challenge with a cumulative methacholine dose ≤2400 µg.

Seeking to follow the indications of guidelines[1] and adapting these to our data, we also took into consideration subjects with PD$_{20}$≤100, 100 <PD$_{20}$≤400, and PD$_{20}$>400 affected by moderate-to-severe, mild, and borderline BHR to evaluate the effect of the season on different levels of BHR.

FEV$_1$ was measured before and during the challenge using a spirometer HP 47120E Pulmonary System Desk (Hewlett Packard, Waltham, Massachusetts, USA). PD$_{20}$, FEV$_1$, was calculated by linear interpolation of the dose response curves. The FEV$_1$, measured before inhaling the buffer solution was considered as the baseline value, whereas the FEV$_1$, measured after the buffer solution was used as the referral to calculate FEV$_1$ decrease and therefore obtain the PD$_{20}$ value. FEV$_1$ and FVC were expressed as percentages of the predicted value, whereas FEV$_1$/FVC was reported only as a ratio (reference equation: CECA, 1971).

**Statistical analysis**

Categorical variables are expressed as percentages. All continuous variables are expressed as mean values,
accompanied by their standard deviations. PD_{20} was logarithmically transformed and therefore expressed as mean and standard deviation. The prevalence of BHR and PD_{20} values, found in the different seasons and in each month, were compared in each sub-group considered. The seasonal and monthly comparisons among the various groups were made by the ANOVA and Chi-square where appropriate. Post-hoc prevalence comparisons were made by the $\chi^2$ test with Bonferroni correction; the Bonferroni test was also used as a post-hoc test for non-parametric data. Baseline FEV\textsubscript{1}, FEV\textsubscript{1}/FVC, and FEV\textsubscript{1}/FVC measured in the various seasons were compared by ANOVA test with Bonferroni test as post-hoc analysis.

The logistic binary regression model was used to evaluate whether age, sex (females in comparison with males), smoking habits, BMI (overweight/obese compared with underweight/normal weight subjects), FEV\textsubscript{1}, and the seasons could be independent BHR risk factors, using PD_{20} < or >2400 $\mu$g as a limit to identify hyper-responsive or normal subjects. Another model was also applied to evaluate whether the above-mentioned covariates were also a risk for a higher degree of severity in hyper-responsiveness (using 400 $\mu$g as a limit of low or high level of hyper-responsiveness). All above-mentioned covariates were included in the models. The risk factor for BHR in winter, spring, and autumn were calculated by comparing these seasons with the summer season which was used as a reference in the logistic regression model. Logistic regression models were used only for those subjects whose smoking history was known (4 169 subjects). $P$ values <0.05 were considered as statistically significant. The statistical packages SPSS (16.0) and MedCalc (9.0.1) were used for the analysis.

**Results**

Among the 4826 subjects (50.53% males), 1 981 (41%) had a normal BHR as their PD_{20} was not obtained after inhaling the maximum dose of methacholine provided by the challenge. All the other BHR subjects showed a LogPD_{20} of 2.52±0.5 $\mu$g. Current smokers were 831 (20%), but the smoking histories of aex-smokers 81 (7.4) and females 642 (51.1) were less in summer than in autumn ($P=0.03$). We also found that overweight or obese hyper-responsive subjects were significantly higher in number in autumn than in the other seasons ($P=0.017$). Non-smoking hyper-responsive subjects were less in summer than in autumn ($P=0.001$).

Subjects with BHR were more frequently found in autumn (789 subjects - 62.3%) than in summer (583 subjects - 56.7%; $P<0.05$) than during the other seasons: 1256 (26%) in winter, 1275 (26.4%) in spring, and 1266 (26.2%) in autumn [Table 1]. Among the seasons, no differences were found in the values of FEV\textsubscript{1}, (% of predicted) and FVC (% of predicted); only the FEV\textsubscript{1}/FVC ratio measured in summer was higher in comparison with autumn ($P=0.022$; [Table 1]). One hundred four subjects showed a PD_{20} between 2400 and 3 200 $\mu$g, but having chosen a 2400 $\mu$g cumulative methacholine dose as the normal cut-off value, they were considered as subjects with normal reactivity.

When subjects with severe-to-moderate, mild, and borderline BHR were taken into consideration, no differences were found in the prevalence of BHR among the four seasons [Figure 1]. Also, when these groups were subdivided into smokers and non-smokers, we did not find any differences in the prevalence of BHR among the four seasons.

The mean LogPD_{20} value, which we found in spring, was lower in comparison with the one measured in summer ($P<0.05$) when subjects were considered as a whole [Table 3]. In particular, LogPD_{20} was lower in females ($P=0.042$) and in non-smokers ($P=0.030$) in spring compared with that in summer. In child-adolescent subjects (age <20 years old), the LogPD_{20} value measured in autumn was lower in comparison with the one observed in winter ($P=0.048$).

When a sub-analysis was performed considering smoking as a confounding factor, we found a lower LogPD_{20} value both in smoking and in non-smoking females in spring compared with summer ($P<0.05$). In non-smoking subjects aged between 20 and 35 years, the value of LogPD_{20} was also lower in spring

---

**Table 1: Characteristics of 4,826 subjects who performed a methacholine challenge test at baseline**

| January to March (Winter) (%) | April to June (Spring) (%) | July to September (Summer) (%) | October to December (Autumn) (%) | Total (%) | $P$ |
|-----------------------------|---------------------------|-------------------------------|-------------------------------|----------|----|
| No. of subjects (% of total) |                          |                               |                               |          |    |
| 1256 (26.0)*                 | 1275 (26.4)*              | 1029 (21.3)**                 | 1266 (26.2)*                  | 4826 (100)| 0.001 |
| Age                         |                           |                               |                               |          |    |
| 36.1 ± 16.6                 | 34.5 ± 16.1               | 35.0 ± 15.8                   | 34.9 ± 16.1                   | 35.1 ± 16.2| 0.084 |
| Male                        |                           |                               |                               |          |    |
| 24.8 ± 4.6                  | 24.7 ± 5.1                | 24.5 ± 4.5                    | 24.7 ± 4.7                    | 24.7 ± 4.7| 0.598 |
| Males                       |                           |                               |                               |          |    |
| 614 (48.9)*                 | 692 (54.3)*               | 505 (49.1)                    | 628 (49.6)                    | 243 (50.5)| 0.020 |
| Females                     |                           |                               |                               |          |    |
| 642 (51.1)*                 | 583 (47.7)*               | 524 (50.9)                    | 638 (50.4)                    | 2387 (49.5)| 0.020 |
| *Current smokers            |                           |                               |                               |          |    |
| 212 (19.3)                  | 215 (19.3)                | 170 (19.7)                    | 234 (21.7)                    | 831 (20) | 0.431 |
| *ex-smokers                 |                           |                               |                               |          |    |
| 81 (7.4)                    | 69 (6.2)                  | 76 (8.8)                      | 69 (6.4)                      | 295 (7.1) | 0.707 |
| Overweight/obese subjects   |                           |                               |                               |          |    |
| 551 (43.9)                  | 540 (42.4)                | 412 (40)                      | 551 (43.5)                    | 2054 (42.6)| 0.255 |
| FVC % of predicted          |                           |                               |                               |          |    |
| 98.8 ± 13.3                 | 99.4 ± 13.4               | 99.7 ± 12.8                   | 100 ± 12.6                    | 99.5 ± 13.0| 0.090 |
| FEV % of predicted          | 100.6 ± 13.1              | 101.3 ± 13.1                  | 101.6 ± 12.8                  | 101.1 ± 12.9| 0.333 |
| FEV/FVC                     | 86 ± 7.0                  | 86.3 ± 7.1                    | 86.3 ± 7.1                    | 86.5 ± 7.1| 0.022 |

BMI = body mass index; FEV\textsubscript{1} = forced expiratory volume in one second; FVC = forced vital capacity; FVC = forced vital capacity. Data were expressed as proportion and mean±standard deviation; % of groups represents the percentage of subjects belonging to the season in which the methacholine tests were performed. Mean comparisons were made by using ANOVA test and a post-hoc analysis with Bonferroni test. Proportion comparisons were made by using $\chi^2$ test and a post-hoc analysis by $\chi^2$ test with Bonferroni correction; **statistically significant differences between groups when they were compared. *evaluated on 4 154 patients.
Table 2: Prevalence of bronchial hyper-responsiveness obtained in the different seasons in the various sub-groups

|                         | January to March (Winter) (%) | April to June (Spring) (%) | July to September (Summer) (%) | October to December (Autumn) (%) | P     |
|-------------------------|-------------------------------|---------------------------|-------------------------------|----------------------------------|-------|
| All BHR subjects (PD<2400 µg) | 727/1256 (57.9)              | 746/1275 (58.5)           | 583/1029 (56.7)*               | 789/1266 (62.3)*                 | 0.03  |
| Males                   | 353/614 (57.5)               | 399/692 (57.2)            | 273/505 (54.1)                | 360/628 (57.3)                   | 0.58  |
| Females                 | 374/642 (58.3)*              | 347/583 (59.5)*           | 310/524 (59.2)*               | 429/638 (67.2)**                 | 0.003 |
| Age <20 years old       | 172/253 (68.0)               | 190/281 (67.6)            | 127/209 (60.8)                | 170/258 (65.9)                   | 0.347 |
| Age between 20 and 35 years old | 225/383 (58.7)           | 266/431 (61.7)            | 198/350 (56.6)                | 272/433 (62.8)                   | 0.271 |
| Age between 36 and 51 years old | 202/361 (56.0)            | 170/332 (51.2)            | 160/276 (58.0)                | 209/342 (61.1)                   | 0.071 |
| Age >/=52 years old     | 128/259 (49.4)               | 120/231 (51.9)            | 98/194 (50.5)                 | 138/233 (59.2)                   | 0.137 |
| Normal weight or underweight | 416/705 (59.0)            | 442/735 (60.1)            | 350/617 (56.7)                | 435/715 (60.8)                   | 0.452 |
| Overweight or obese     | 311/551 (56.4)*              | 304/540 (56.3)*           | 233/412 (56.6)*               | 354/551 (64.2)**                 | 0.017 |
| Smokers                 | 132/212 (62.3)               | 143/215 (66.5)            | 112/170 (65.9)                | 148/234 (63.2)                   | 0.768 |
| Non-smokers             | 505/889 (56.8)               | 507/897 (56.5)            | 358/694 (51.6)*               | 526/843 (62.4)*                  | 0.001 |

BHR - bronchial hyper-responsiveness. The subjects who obtained a 20% fall in FEV1 with a methacholine dose of 2 400 µg were considered as hyper-responsive, evaluated on 4,154 patients. *Statistically significant differences between groups when they were compared. Data were expressed as mean±standard deviation; P value calculated with Chi-square test whereas post-hoc comparisons were made by χ² test with Bonferroni correction.

Table 3: Seasonal values of LogPD20 obtained in 2,845 subjects with BHR subdivided into various sub-groups

|                         | January to March (Winter) (%) | April to June (Spring) (%) | July to September (Summer) (%) | October to December (Autumn) (%) | P     |
|-------------------------|-------------------------------|---------------------------|-------------------------------|----------------------------------|-------|
| All BHR subjects (PD20<2 400 µg) | 2.53 ± 0.51                   | 2.48 ± 0.48*              | 2.59 ± 0.49*                  | 2.51 ± 0.52                      | 0.050 |
| Males                   | 2.53 ± 0.49                   | 2.51 ± 0.48               | 2.53 ± 0.49                   | 2.48 ± 0.51                      | 0.580 |
| Females                 | 2.53 ± 0.53                   | 2.49 ± 0.50*              | 2.6 ± 0.49*                   | 2.53 ± 0.53                      | 0.042 |
| Age <20 years old       | 2.56 ± 0.47*                  | 2.46 ± 0.46               | 2.47 ± 0.52                   | 2.42 ± 0.53*                     | 0.048 |
| Age between 20 and 35 years old | 2.51 ± 0.52                   | 2.48 ± 0.51               | 2.57 ± 0.51                   | 2.51 ± 0.52                      | 0.316 |
| Age between 36 and 51 years old | 2.51 ± 0.53                   | 2.54 ± 0.49               | 2.62 ± 0.48                   | 2.53 ± 0.53                      | 0.140 |
| Age >/=52 years old     | 2.57 ± 0.54                   | 2.55 ± 0.49               | 2.62 ± 0.41                   | 2.59 ± 0.49                      | 0.786 |
| Normal weight or underweight | 2.56 ± 0.50                   | 2.49 ± 0.50               | 2.56 ± 0.51                   | 2.53 ± 0.53                      | 0.163 |
| Overweight or obese     | 2.49 ± 0.49                   | 2.51 ± 0.47               | 2.59 ± 0.46                   | 2.48 ± 0.51                      | 0.058 |
| Smokers                 | 2.53 ± 0.51                   | 2.51 ± 0.49               | 2.58 ± 0.50                   | 2.49 ± 0.53                      | 0.080 |
| Non-smokers             | 2.58 ± 0.50                   | 2.48 ± 0.48*              | 2.65 ± 0.46*                  | 2.61 ± 0.51                      | 0.030 |
| Moderate to Severe BHR  | 1.71 ± 0.22                   | 1.74 ± 0.21               | 1.73 ± 0.23                   | 1.71 ± 0.22                      | 0.687 |
| Mild BHR                | 2.34 ± 0.17                   | 2.34 ± 0.17               | 2.33 ± 0.17                   | 2.35 ± 0.17                      | 0.555 |
| Borderline BHR          | 2.99 ± 0.22                   | 2.96 ± 0.21               | 2.99 ± 0.21                   | 3 ± 0.22                        | 0.171 |

BHR = Bronchial hyper-responsiveness. Subjects with PD20 ≤100, 100< PD20 ≤400, and PD20>400 were considered to be affected by moderate-to-severe, mild, and borderline BHR; see Table 2 for statistical analysis. *Statistically significant differences between groups when they were compared. Data were expressed as mean±standard deviation; P value was calculated using ANOVA test; post-hoc multiple comparisons among groups were calculated by using Bonferroni test.

The month-to-month comparisons of the LogPD20 values and the prevalence of hyper-responsiveness according to severity did not show any significant differences [Figure 2].

The logistic regression model [Table 4] showed a significantly higher BHR risk in females (Odd Ratio [OR]: 1.536; P=0.001), smokers (OR: 1.279; P=0.003), overweight or obese subjects (OR: 1.219; P=0.005), whereas age and FEV1% were protective factors (increasing their values, the risk of being hyper-responsive decreased). Among the seasons, autumn showed a significantly higher BHR risk (OR: 1.378; P=0.001) compared with summer. Spring (OR: 1.331; P=0.020) were also risk factors for a higher degree of severity in BHR (using a PD20<400 µg as BHR limit; [Table 4]), when summer was used as a reference season.
Discussion

This study, carried out on a large number of subjects, highlights that some seasons may influence the results of methacholine challenge tests. In fact, a lower number of hyper-responsive subjects were found in summer compared with autumn. Furthermore, the logistic regression models showed a higher (+39.3%) bronchial risk of hyper-responsiveness in autumn in comparison with summer when we chose a 2400 µg cut-off value to divide hyper-responsive subjects from normal subjects. There was also a higher risk (+34.7%) for a higher degree of severity in airway hyper-responsiveness (using a cut-off of 400 µg) both in spring and in autumn, again compared with summer. This result is certainly due to a greater allergen exposure in these seasons in comparison with summer. This major exposure may cause an increase in airway inflammation with a consequent increase in BHR. Blood eosinophil numbers were indeed higher in BHR subjects with seasonal allergic rhinitis during pollen season than those without BHR, whereas there was no difference in the number of these cells during off-season in these two groups. After a nasal challenge with grass pollen in rhinitis, BHR and both eosinophil numbers and eosinophil-cationic protein (ECP) concentration in induced sputum had increased and the latter two were correlated to methacholine responsiveness. In addition, eosinophils and ECP, both in peripheral blood and sputum, increased in mite-sensitized asthmatic subjects after Dermatophagoides pteronyssinus exposure and this rise was associated to a PD$_{20}$ decrease. Fruchter and Yigla, in a similar study, partially confirmed our results as they found a lower number of positive methacholine tests in summer compared with winter and spring, due to a lower allergy burden in mites and in pollens in that season. Another study also showed that the sensitivity of exercise testing for asthma in adolescents is halved in summer due to a decreased asthma activity for a lower exposure to allergens, to air pollutants such as nitrogen oxides and sulfur dioxide and to respiratory viruses such as respiratory syncytial virus and influenza.

Other authors have found, in agreement with our study, a greater autumnal airway hyper-responsiveness risk. In fact, some of them had already observed how airway hyper-responsiveness increased in autumn in multiple-sensitized allergic asthmatic patients. The higher prevalence of BHR in autumn is probably due to an increased exposure to house dust mite in this season. In fact, a more severe airway hyper-responsiveness was found in mite-sensitized patients and this was strongly related to an increase of Der p 1 concentrations in floor dust, particularly at the beginning of autumn. Other authors have also found that sensitization to house dust mite, as opposed to sensitization to pollen allergens alone, is associated with BHR, thus confirming that mite allergy plays the leading role in BHR. Unfortunately, in our study, the allergic status of the subjects recruited is not known. However, it seems that 95.4% of young adults, with positive methacholine tests, resulted positive to aeroallergen skin prick tests. We found a positive skin prick test in approximately 64% of a group of 811 subjects recruited in the same Tuscan area for suspected rhinitis and/or asthma. We found a higher sensitization to mites (61.8%), followed by cypress (56%), grasses (44%), olea (36.4%), and pellitory (19.6%) in these subjects. Therefore, among the 4826 subjects considered for our study, a large number of them might be allergic to house dust mites, thus influencing the variations in autumnal airway hyper-responsiveness. However, also atopic asthmatic subjects—who are exposed to high levels of dust mites (as it may happen in autumn) but not sensitized to this allergen—show evidence of increased airway reactivity.

The increased mite-induced airway inflammation may also explain the increased obstruction of the airways in autumn demonstrated by a reduced FEV$_1$/FVC ratio found in this season compared with summer. Consequently, this autumnal increased obstruction may be responsible for the higher prevalence of BHR found in this season. In fact, it is known that the level of BHR is negatively correlated to pulmonary function. The autumnal drop in temperature, with the increase of upper or lower respiratory tract infections, might be another reason for the higher prevalence of hyper-responsiveness in autumn. In fact, some studies correlated bronchial infections with an increased airway hyper-responsiveness. However, the absence of any BHR increase in winter, when bronchial infections were more frequent, does not explain this increase in hyper-responsiveness in autumn. On the contrary, Fruchter and Yigla found a higher prevalence of BHR in winter and not in autumn. It is known that in Israel, in particular in Haifa where the study was performed, the climate is usually...
milder if compared with that of Northern Italy, which makes the Israeli winter similar to the Italian autumn. A very high humidity rate and very cold air may also influence airway hyper-responsiveness,\[12,13\] but humidity and the temperature in autumn do not usually reach extreme values in our area. Therefore, any direct influence of temperature and/or humidity on this BHR variability is unlikely.

Another important result of this study was the observation of a lower PD\textsubscript{20} value in spring compared with summer. Furthermore, we found that there was a higher probability of having a PD\textsubscript{20} lower than 400 \( \mu \)g in spring compared with the summer. This means that the higher pollen concentrations in spring, due to blooming of grasses, olea, and pellitory in our area, can determine a more severe BHR in subjects sensitized to these pollens. This is confirmed by some studies that have shown an increase in bronchial reactivity in spring in hyper-responsive subjects with rhinitis and/or asthma sensitized to Parietaria, Olea, and Gramineae.\[2-6\] It seems that Parietaria is more important than Olea and Gramineae as a risk factor for non-specific BHR.\[30\]

Our study highlighted that seasonal variability concerns particularly females and overweight/obese subjects. The prevalence of hyper-responsiveness in these subjects was higher in autumn in comparison with what was obtained in the other seasons, which was unexpected. Furthermore, the PD\textsubscript{20} value was lower in females and in non-smoker overweight/obese subjects in spring compared with that in summer (eliminating the confounding effect of smoking). We have not found any explanations in literature for this greater prevalence of hyper-responsiveness in autumn and this greater hyper-reactivity in spring, in particular in these categories of subjects. Several studies have shown that the female sex has a higher BHR risk factor\[18,29,30\] as confirmed also in our study (+53.6% of risk increase). It has been suggested that the higher prevalence of airway hyper-responsiveness in females could be caused by their smaller lung volumes.\[27\] On the other hand, there are conflicting studies on a possible existence of a relation between BMI and hyper-responsiveness.\[31-34\] However, we found that an overweight/obese status is an independent risk both in autumn and spring. Therefore, subjects with PD\textsubscript{20}<400 \( \mu \)g (with a higher BHR) may show a worsening of BHR in these seasons.

This study also confirmed how smoking can be a BHR risk factor (+27.9%) in subjects with typical asthma respiratory symptoms. Other studies had already observed how asymptomatic smokers showed an increased airway responsiveness compared with non-smokers.\[36,37\] Furthermore, allergic rhinitis (+/- asthma) hyper-responsive subjects showed an improvement in methacholine-induced BHR 12 months after they had stopped smoking, thus confirming the importance of such habit in BHR.\[38\] Smoking can cause chronic airway neutrophilic inflammation and oxidative epithelium damage, thus leading to the development of airway hyper-responsiveness.\[39\] In fact, a dose-dependent relationship between the number of cigarettes smoked and the degree of hyper-responsiveness has been demonstrated.\[40\] A large number of non-smokers showed a BHR in autumn compared with what was found in summer, whereas no seasonal variations were observed in smokers. Smoking probably induces a persistent inflammation or the worsening of the pre-existent inflammation induced by asthma which cancels the seasonal changes in BHR over the course of the year. The absence of smoke-induced inflammation makes this airway phlogosis susceptible to allergen-related seasonal changes in non-smokers.

We also analyzed if there were any seasonal variations in the different levels of BHR. We did not find any differences neither in prevalence nor in PD\textsubscript{20} among the seasons in moderate-to-severe, mild, and borderline BHR. However, according to the guidelines,\[11\] the PC\textsubscript{20} cut-off value for a positive methacholine test is 4 mg/ml, comparable with our PD\textsubscript{20} dose of 400 \( \mu \)g. Using a cut-off value of 400 \( \mu \)g to define BHR in the logistic regression model, we found a high BHR risk both in autumn and spring. Therefore, subjects with PD\textsubscript{20}<400 \( \mu \)g may show a worsening of BHR in these seasons.

We must also add that the results seem to be in contradiction where the prevalence of BHR was higher in autumn while the PD\textsubscript{20} was lower in the spring. This may be due to a higher proportion of subjects with severe BHR in spring (although not significant) compared with summer, but in autumn, we observed that the distribution of subjects with different levels of BHR is the same as that observed in spring. Alternatively, this increased BHR in spring could be due to a greater activity on the airways by spring allergens; on the contrary, autumnal allergens may cause a reduced bronchial reaction in subjects with BHR.

In summary, this study has shown a seasonal variability of airway hyper-responsiveness; therefore, when methacholine tests are repeatedly performed over the course of time (for example, in clinical trials), this must be taken into account. In addition, considering that there is a lower BHR in summer, especially in comparison with spring and autumn, a reduced therapy level in this season may be hypothesized in multi-sensitized persistent asthmatics, whereas in autumn and spring—when their BHR is higher—treatments may be increased.

In conclusion, this study has shown a seasonal variability in the response to the methacholine challenge test in subjects with suggestive asthma symptoms, which is probably due to a different allergens exposure in the various seasons. A higher probability of finding a hyper-responsiveness may be detected.
in autumn and in spring, whereas a lower one may be found in summer. Spring is the season when BHR may be more severe. This seasonal variability seems to concern in particular females and overweight-obese subjects.

Acknowledgment

We acknowledge Prof. Piero Angelo Lenzi and Tina Parisi for your professional and linguistic editing.

References

1. Crapo RO, Casaburi R, Coates AL, Enright PL, Hankinson JL, Irvin CG, et al. Guidelines for metacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med 2000;161:309-29.

2. Tilles SA, Bardana EJ Jr. Seasonal variation in bronchial hyper-responsiveness in allergic patients. Clin Rev Allergy Immunol 1997;15:169-85.

3. Riccioni G, Di Stefano F, De Benedictis M, Verna N, Cavallucci E, Paolini F, et al. Seasonal variability of non-specific hyper-responsiveness in asthmatic patients with allergy to house dust mites. Allergy Asthma Proc 2001;22:5-9.

4. Beier J, Beeh KM, Kornmann O, Morankie E, Ritter N, Buhl R. Dissimilarity between seasonal changes in airway responsiveness to adenosine-5'-monophosphate and methacholine in patients with grass pollen allergic rhinitis: Relation to induced sputum. Int Arch Allergy Immunol 2003;132:76-81.

5. Orhan F, Sekerel BE, Adalioglu G, Pinar M, Tuncer A. Effect of nasal trimcinolone acetonide on seasonal variations of bronchial hyperresponsiveness and bronchial inflammation in nonasthmatic children with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2004;92:438-45.

6. Currie GP, Jackson CM, Lee DK, Lipworth BJ. Determinants of airway hyperresponsiveness in mild asthma. Ann Allergy Asthma Immunol 2003;90:560-3.

7. van der Heide S, de Monchy JG, de Vries K, Dubois AE, Kauffman HF. Seasonal differences in airway hyperresponsiveness in asthmatic patients: Relationship with allergen exposure and sensitization to house dust mites. Clin Exp Allergy 1997;27:627-33.

8. van der Heide S, de Monchy JG, de Vries K, Kauffman HF. Seasonal variation in airway hyperresponsiveness and natural exposure to house dust mite allergens in patients with asthma. J Allergy Clin Immunol 1994;93:470-5.

9. Wennergren G. Impact of viral infection bronchial hyper-responsiveness. Pediatr Allergy Immunol 1996;7:10-13.

10. Busse WW. Respiratory infections: Their role in airway hyperresponsiveness and the pathogenesis of asthma. J Allergy Clin Immunol 1990;85:671-83.

11. Eggleston PA. Upper airway inflammatory diseases and bronchial hyperresponsiveness. J Allergy Clin Immunol 1988;81:1036-41.

12. Langdeau JB, Turcotte H, Bowie DM, Jobin J, Desgagnè P, et al. Changes in airway inflammation following nasal allergen challenge in patients with seasonal rhinitis. Allergy 2000;55:331-9.

13. Goldberg S, Schwartz S, Izbicki G, Belisha-Hamami R, Picard E. Sensitivity of exercise testing for asthma in adolescent is halved in the summer. Chest 2005;128:2408-11.

14. Kerkhof M, Postma DS, Schouten JP, de Monchy JG. Allergic sensitization to indoor and outdoor allergens and relevance to bronchial hyperresponsiveness in younger and older subjects. Allergy 2003;58:1261-7.

15. Sposato B, Scalese M. Prevalence and real clinical impact of Cupressus sempervirens and Juniperus communis sensitization in Tuscan “Maremma” Italy. Allergol Immunopathol 2011;in press; doi: 10.1016/j.aller.2011.08.001.

16. Langley SJ, Goldthorpe S, Craven M, Woodcock A, Custovic A. Relationship between exposure to domestic allergens and bronchial hyperresponsiveness in non-sensitised, atopic asthmatic subjects. Thorax 2005;60:17-21.

17. Sunyer J, Anto JM, Kogevinas M, Soriano JB, Tobias A, Munoz A. Smoking and bronchial responsiveness in nonatopic and atopic young adults. Spanish group of the European study of asthma. Thorax 1997;52:235-8.

18. Paoletti P, Carrozzini L, Vieggi G, Modena P, Ballerin L, Di Pede F, et al. Distribution of bronchial responsiveness in a general population: Effect of sex, age, smoking and level of pulmonary function. Am J Respir Crit Care Med 1995;151:1770-7.

19. Cole TJ, Bellizzi MC, Flegal KM, Mathison DA, MacLean JA, Rosenthal RR, et al. Standardization of bronchial inhalation challenge procedure. J Allergy Clin Immunol 1975;56:323-7.

20. Kurt E, Aktas A, Gulbas Z, Erginel S, Arslan S. The effect of natural pollen exposure on inflammatory cytokines and their relationship with nonspecific bronchial hyperresponsiveness in seasonal allergic rhinitis. Allergy Asthma Proc 2010;31:126-31.

21. Bony M, Neukirch C, Grandaige M, Lecon-Malas V, Ravaud P, Dehoux M, et al. Changes in airway inflammation following nasal allergen challenge in patients with seasonal rhinitis. Allergy 2006;61:111-8.

22. Alvarez MJ, Olaguebel JM, Garcia BE, Tabar AL, Uribia E. Comparison of allergen-induced changes in bronchial hyperresponsiveness and airway inflammation between mildly allergic asthma patients and allergic rhinitis patients. Allergy 2000;55:331-9.

23. Alvarez MJ, Olaguebel JM, Garcia BE, Tabar AL, Uribia E. Comparison of allergen-induced changes in bronchial hyperresponsiveness and airway inflammation between mildly allergic asthma patients and allergic rhinitis patients. Allergy 2000;55:331-9.

24. Britton J, Pavord I, Richards K, Knox A, Wisniewski A, Wahedna I, et al. Factors influencing the occurrence of airway hyperreactivity in the general population. Chest 1988;93:26-30.

25. Britton J, Pavord I, Richards K, Knox A, Wisniewski A, Wahedna I, et al. Factors influencing the occurrence of airway hyperreactivity in the general population: The importance of atopy and airway calibre. Eur Respir J 1994;7:881-7.

26. Di Lorenzo G, Mansueto P, Melluso M, Morici G, Norrito F, Esposito Pellitteri M, et al. Non-specific airway hyperresponsiveness in mono-sensitive Sicilian patients with allergic rhinitis. Its relationship to total serum IgE levels and blood eosinophils in mono-sensitive patients. Thorax 2005;60:17-21.

27. Britton J, Pavord I, Richards K, Knox A, Wisniewski A, Wahedna I, et al. Factors influencing the occurrence of airway hyperreactivity in the general population: The importance of atopy and airway calibre. Eur Respir J 1994;7:881-7.

28. Britton J, Pavord I, Richards K, Knox A, Wisniewski A, Wahedna I, et al. Factors influencing the occurrence of airway hyperreactivity in the general population: The importance of atopy and airway calibre. Eur Respir J 1994;7:881-7.

29. Britton J, Pavord I, Richards K, Knox A, Wisniewski A, Wahedna I, et al. Factors influencing the occurrence of airway hyperreactivity in the general population: The importance of atopy and airway calibre. Eur Respir J 1994;7:881-7.

30. Britton J, Pavord I, Richards K, Knox A, Wisniewski A, Wahedna I, et al. Factors influencing the occurrence of airway hyperreactivity in the general population: The importance of atopy and airway calibre. Eur Respir J 1994;7:881-7.

31. Schachter LM, Salome CM, DeMolles D, Weiss ST. Association of body mass index with the development of methacholine airway hyperresponsiveness in men: The Normative Aging Study. Thorax 2002;57:1028-33.

32. Schachter LM, Salome CM, DeMolles D, Weiss ST. Association of body mass index with the development of methacholine airway hyperresponsiveness in men: The Normative Aging Study. Thorax 2002;57:1028-33.
35. Beuther DA, Weiss ST, Sutherland ER. Asthma and obesity. Am J Respir Crit Care Med 2006;174:112-9.
36. Jensen EJ, Dahl R, Steffensen F. Bronchial reactivity to cigarette smoke in smokers: Repeatability, relationship to methacholine reactivity, smoking and atopy. Eur Respir J 1998;11:670-6.
37. Jðgi R, Janson C, Boman G, Bjãrklstãn B. Bronchial hyperresponsiveness in two populations with different prevalences of atopy. Int J Tuberc Lung Dis 2004;8:1180-5.
38. Piccillo G, Caponnetto P, Barton S, Russo C, Origlio A, Bonaccorsi A, et al. Changes in airway hyperresponsiveness following smoking cessation: Comparisons between Mch and AMP. Respir Med 2008;102:256-65.
39. Chalmers GW, MacLeod KJ, Thomson L, Little SA, McSharry C, Thomson NC. Smoking and airway inflammation in patients with mild asthma. Chest 2001;120:1917-22.
40. Gerrard JW, Cockcroft DW, Mink JT, Cotton DJ, Poonawala R, Dosman JA. Increased nonspecific bronchial reactivity in cigarette smokers with normal lung function. Am Rev Respir Dis 1980;122:577-81.

How to cite this article: Sposato B, Scalese M, Pammolli A, Scala R, Naldi M. Seasons can influence the results of the methacholine challenge test. Ann Thorac Med 2012;7:61-8.

Source of Support: Nil, Conflict of Interest: None declared.